A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.

A unique heterocyclic carbamate prodrug of seco-CBI-indole(2) that releases no residual byproduct is reported as a new member of a class of hydrolyzable prodrugs of the duocarmycin and CC-1065 family of natural products. The prodrug was designed to be activated by hydrolysis of a carbamate releasing the free drug without the cleavage release of a traceable extraneous group. Unlike prior carbamate prodrugs examined that are rapidly cleaved in vivo, the cyclic carbamate was found to be exceptionally stable to hydrolysis under both chemical and biological conditions providing a slow, sustained release of the exceptionally potent free drug. An in vivo evaluation of the prodrug found that its efficacy exceeded that of the parent drug, that its therapeutic window of efficacy versus toxicity is much larger than the parent drug, and that its slow free drug release permitted the safe and efficacious use of doses 150-fold higher than the parent compound.

[1]  R. Chari,et al.  Synthesis and biological evaluation of antibody conjugates of phosphate prodrugs of cytotoxic DNA alkylators for the targeted treatment of cancer. , 2012, Journal of medicinal chemistry.

[2]  W. Denny,et al.  Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins. , 2011, Angewandte Chemie.

[3]  D. Boger,et al.  Asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI). , 2011, The Journal of organic chemistry.

[4]  D. Boger,et al.  Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activation. , 2010, Journal of medicinal chemistry.

[5]  D. Boger,et al.  Fundamental relationships between structure, reactivity, and biological activity for the duocarmycins and CC-1065. , 2009, Journal of medicinal chemistry.

[6]  Lian-Sheng Li,et al.  Studies toward the duocarmycin prodrugs for the antibody prodrug therapy approach. , 2009, Tetrahedron letters.

[7]  D. Boger,et al.  Total synthesis and evaluation of iso-duocarmycin SA and iso-yatakemycin. , 2009, Journal of the American Chemical Society.

[8]  D. Boger,et al.  Yatakemycin: Total Synthesis, DNA Alkylation, and Biological Properties , 2008 .

[9]  L. Tietze,et al.  Duocarmycin-based prodrugs for cancer prodrug monotherapy. , 2008, Bioorganic & medicinal chemistry.

[10]  D. Boger,et al.  A unique class of duocarmycin and CC-1065 analogues subject to reductive activation. , 2007, Journal of the American Chemical Society.

[11]  D. Boger,et al.  Systematic exploration of the structural features of yatakemycin impacting DNA alkylation and biological activity. , 2007, Journal of the American Chemical Society.

[12]  D. Boger,et al.  Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer. , 2006, Journal of the American Chemical Society.

[13]  J. Larrick,et al.  Synthesis and antitumor activity of CBI-bearing ester and carbamate prodrugs of CC-1065 analogue. , 2006, Bioorganic & medicinal chemistry.

[14]  L. Tietze,et al.  Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy. , 2006, Angewandte Chemie.

[15]  D. Boger,et al.  Alkylation of duplex DNA in nucleosome core particles by duocarmycin SA and yatakemycin , 2006, Nature chemical biology.

[16]  Dale L Boger,et al.  Sequence-selective DNA recognition: natural products and nature's lessons. , 2004, Chemistry & biology.

[17]  D. Boger,et al.  Total Synthesis, Structure Revision, and Absolute Configuration of (+)‐Yatakemycin. , 2004 .

[18]  D. Boger,et al.  Effective asymmetric synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benzo[e]indol-4-one (CBI). , 2004, The Journal of organic chemistry.

[19]  D. Boger,et al.  Establishing the parabolic relationship between reactivity and activity for derivatives and analogues of the duocarmycin and CC-1065 alkylation subunits. , 2004, Journal of the American Chemical Society.

[20]  W. Denny,et al.  Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with nitroreductase-mediated gene-directed enzyme prodrug therapy. , 2003, Journal of medicinal chemistry.

[21]  D. Boger,et al.  DNA alkylation properties of yatakemycin. , 2003, Journal of the American Chemical Society.

[22]  D. Boger,et al.  Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065. , 2003, Bioorganic & medicinal chemistry.

[23]  H. Naoki,et al.  Yatakemycin, a novel antifungal antibiotic produced by Streptomyces sp. TP-A0356. , 2003, The Journal of antibiotics.

[24]  D. Boger,et al.  Mechanisms of in situ Activation for DNA-Targeting Antitumor Agents , 2002 .

[25]  M. Searcey.  Duocarmycins--natures prodrugs? , 2002, Current pharmaceutical design.

[26]  S. Buchwald,et al.  New Ammonia Equivalents for the Pd‐Catalyzed Amination of Aryl Halides. , 2002 .

[27]  Erik C. Madsen,et al.  Investigation of a novel reductively-activatable anticancer prodrug of seco -CBI-TMI, an analog of duocarmycin SA , 2002 .

[28]  L. Tietze,et al.  A strategy for tumor-selective chemotherapy by enzymatic liberation of seco-duocarmycin SA-derivatives from nontoxic prodrugs. , 2001, Bioorganic & medicinal chemistry.

[29]  D. Boger,et al.  Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction , 1999 .

[30]  D. Boger,et al.  A Novel Class of CC-1065 and Duocarmycin Analogues Subject to Mitomycin-Related Reductive Activation. , 1999, The Journal of organic chemistry.

[31]  W. Denny,et al.  A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. , 1999, Bioorganic & medicinal chemistry letters.

[32]  D. Boger,et al.  CBI Prodrug Analogs of CC-1065 and the Duocarmycins , 1999 .

[33]  J. Beijnen,et al.  Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans. , 1998, Cancer research.

[34]  D. Boger,et al.  Synthesis of CC-1065 and duocarmycin analogs via intramolecular aryl radical cyclization of a tethered vinyl chloride , 1998 .

[35]  D. Boger,et al.  Asymmetric Synthesis of the CBI Alkylation Subunit of the CC-1065 and Duocarmycin Analogs , 1997 .

[36]  D. Boger,et al.  Reversed and Sandwiched Analogs of Duocarmycin SA: Establishment of the Origin of the Sequence-Selective Alkylation of DNA and New Insights into the Source of Catalysis , 1997 .

[37]  D. Boger,et al.  Duocarmycin SA Shortened, Simplified, and Extended Agents: A Systematic Examination of the Role of the DNA Binding Subunit , 1997 .

[38]  D. Boger,et al.  Total Synthesis of (+)-Duocarmycin A, epi-(+)-Duocarmycin A and Their Unnatural Enantiomers: Assessment of Chemical and Biological Properties. , 1997 .

[39]  D. Boger,et al.  CC-1065 and the Duocarmycins: Synthetic Studies. , 1997, Chemical reviews.

[40]  D. Boger,et al.  Catalysis of the CC-1065 and duocarmycin DNA alkylation reaction: DNA binding induced conformational change in the agent results in activation. , 1997, Bioorganic & medicinal chemistry.

[41]  D. Boger,et al.  CC‐1065 and the Duocarmycins: Understanding Their Biological Function Through Mechanistic Studies , 1996 .

[42]  D. Boger,et al.  Synthesis, Chemical Properties, and Preliminary Evaluation of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one Alkylation Subunit: Hammett Quantitation of the Magnitude of Electronic Effects on Functional Reactivity , 1996 .

[43]  D. Boger,et al.  Enantioselective Total Synthesis of (+)-Duocarmycin A, epi-(+)-Duocarmycin A, and Their Unnatural Enantiomers , 1996 .

[44]  D. Boger,et al.  1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) analogs of CC-1065 and the duocarmycins: synthesis and evaluation. , 1995, Bioorganic & medicinal chemistry.

[45]  K. Gomi,et al.  Synthesis and antitumor activity of duocarmycin derivatives. , 1995, Chemical & pharmaceutical bulletin.

[46]  D. Boger,et al.  1,2,9,9a‐Tetrahydrocyclopropa(c)benz(e)indol‐4‐one (CBI): An Enhanced and Simplified Analogue of the CC‐1065 and Duocarmycin Alkylation Subunits. , 1995 .

[47]  D. Boger.  The Duocarmycins: Synthetic and Mechanistic Studies , 1995 .

[48]  D. Boger,et al.  CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit. , 1995, Bioorganic & medicinal chemistry.

[49]  D. Boger,et al.  CC-1065 and the duocarmycins: unraveling the keys to a new class of naturally derived DNA alkylating agents. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Boger,et al.  CBI-TMI: Synthesis and Evaluation of a Key Analog of the Duocarmycins. Validation of a Direct Relationship between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents , 1994 .

[51]  D. Boger,et al.  ROLE OF THE CC-1065 AND DUOCARMYCIN N2 SUBSTITUENT : VALIDATION OF A DIRECT RELATIONSHIP BETWEEN SOLVOLYSIS CHEMICAL STABILITY AND IN VITRO BIOLOGICAL POTENCY , 1994 .

[52]  A. Asai,et al.  Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors. , 1994, Cancer research.

[53]  D. Boger,et al.  (+)- and ent-(-)-Duocarmycin SA and (+)- and ent-(-)-N-BOC-DSA DNA Alkylation Properties.Alkylation Site Models That Accommodate the Offset AT-Rich Adenine N3 Alkylation Selectivity of the Enantiomeric Agents , 1994 .

[54]  D. Boger,et al.  Molecular basis for sequence selective DNA alkylation by (+)- and ent-(-)-CC-1065 and related agents: alkylation site models that accommodate the offset AT-rich adenine N3 alkylation selectivity. , 1994, Bioorganic & medicinal chemistry.

[55]  D. Boger,et al.  Total Synthesis and Preliminary Evaluation of (+)‐ and ent‐(‐)‐ Duocarmycin SA. , 1994 .

[56]  D. Boger,et al.  Reversibility of the duocarmycin A and SA DNA alkylation reaction , 1993 .

[57]  D. Boger,et al.  Total Synthesis of (+)‐Duocarmycin SA. , 1993 .

[58]  W. C. Krueger,et al.  Cytotoxicity and antitumor activity of carzelesin, a prodrug cyclopropylpyrroloindole analogue. , 1992, Cancer research.

[59]  D. Boger,et al.  DNA alkylation properties of enhanced functional analogs of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) alkylation subunit , 1992 .

[60]  D. Boger,et al.  DNA alkylation properties of the duocarmycins: (+)-duocarmycin A, epi-(+)-duocarmycin A, ent-(−)-duocarmycin A and epi,ent-(−)-duocarmycin A , 1992 .

[61]  D. Boger,et al.  An improved synthesis of 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): a simplified analog of the CC-1065 alkylation subunit , 1992 .

[62]  D. Boger,et al.  Isolation and characterization of the duocarmycin-adenine DNA adduct , 1991 .

[63]  D. Boger,et al.  (+)-CC 1065 DNA alkylation : key studies demonstrating a noncovalent binding selectivity contribution to the alkylation selectivity , 1991 .

[64]  D. Boger,et al.  (+)-CC-1065 DNA alkylation : observation of an unexpected relationship between cyclopropane electrophile reactivity and the intensity of DNA alkylation , 1991 .

[65]  D. Boger,et al.  Demonstration of a pronounced effect of noncovalent binding selectivity on the (+)-CC-1065 DNA alkylation and identification of the pharmacophore of the alkylation subunit. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[66]  D. Boger,et al.  Synthesis and preliminary evaluation of (+)-CBI-indole2: an enhanced functional analog of (+)-CC-1065 , 1991 .

[67]  D. Boger,et al.  A potent, simple derivative of an analog of the CC-1065 alkylation subunit , 1991 .

[68]  D. Boger,et al.  An alternative and convenient strategy for generation of substantial quantities of singly 5'-32P-end-labeled double-stranded DNA for binding studies: development of a protocol for examination of functional features of (+)-CC-1065 and the duocarmycins that contribute to their sequence-selective DNA a , 1991, Tetrahedron.

[69]  D. Boger,et al.  Duocarmycin-pyrindamycin DNA alkylation properties and identification, synthesis, and evaluation of agents incorporating the pharmacophore of the duocarmycin-pyrindamycin alkylation subunit. Identification of the CC-1065 duocarmycin common pharmacophore , 1990 .

[70]  D. Boger,et al.  Synthesis of N-(tert-butyloxycarbonyl)-CBI, CBI, CBI-CDPI1, and CBI-CDPI2: enhanced functional analogs of CC-1065 incorporating the 1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) left-hand subunit , 1990 .

[71]  D. Boger,et al.  Synthesis of N-(Phenylsulfonyl)-CI, N-((tert.-Butyloxy)carbonyl)-CI, CI-CDPI1, and CI-CDPI2: CC-1065 Functional Analogues Incorporating the Parent 1,2,7,7a-Tetrahydrocycloprop(1,2-c)indol-4-one (CI) Left-Hand Subunit. , 1990 .

[72]  R. S. Coleman,et al.  Synthesis and Evaluation of Aborted and Extended CC-1065 Functional Analogues: (+)- and (-)-CPI-PDE-I1, (+)- and (-)-CPI-CDPI1, and (.+-.)-, (+)-, and (-)-CPI-CDPI3. Preparation of Key Partial Structures and Definition of an Additiona , 1990 .

[73]  I. Kawamoto,et al.  Duocarmycin SA, a new antitumor antibiotic from Streptomyces sp. , 1990, The Journal of antibiotics.

[74]  R. S. Coleman,et al.  Synthesis and evaluation of aborted and extended CC-1065 functional analogs: (+)- and (-)-CPI-PDE-I1, (+)- and (-)-CPI-CDPI1, and (.+-.)-, (+)-, and (-)-CPI-CDPI3. Preparation of key partial structures and definition of an additional functional role of the CC-1065 central and right-hand subunits , 1990 .

[75]  D. Boger,et al.  Synthesis of N-(phenylsulfonyl)-CI, N-((tert-butyloxy)carbonyl)-CI, CI-CDPI1, and CI-CDPI2: CC-1065 functional analog incorporating the parent 1,2,7,71-tetrahydrocycloprop[1,2-c]indol-4-one (CI) left-hand subunit , 1990 .

[76]  D. Boger,et al.  Resolution of a CBI precursor and incorporation into the synthesis of (+)-cbi, (+)-CBI-CDPI1, (+)-CBI-CDPI2: enhanced functional analogs of (+)-CC-1065. A critical appraisal of a proposed relationship between electrophile reactivity, DNA binding properties, and cytotoxic potency. , 1990 .

[77]  R. S. Coleman,et al.  A demonstration of the intrinsic importance of stabilizing hydrophobic binding and non-covalent van der Waals contacts dominant in the non-covalent CC-1065/B-DNA binding. , 1990, Chemico-biological interactions.

[78]  D. Boger,et al.  Total synthesis and evaluation of (.+-.)-N-(tert-butoxycarbonyl)-CBI, (.+-.)-CBI-CDPI1, and (.+-.)-CBI-CDPI2: CC-1065 functional agents incorporating the equivalent 1,2,9,9a-tetrahydrocyclopropa[1,2-c]benz[1,2-e]indol-4-one (CBI) left-hand subunit , 1989 .

[79]  K. Asano,et al.  Duocarmycin A, a new antitumor antibiotic from Streptomyces. , 1988, The Journal of antibiotics.

[80]  R. S. Coleman,et al.  Total synthesis of (±)-N2-(phenylsulfonyl)-CPI, (±)-CC-1065, (+)-CC-1065, ent-(−)-CC-1065, and the precise, functional agents (±)-CPI-CDPI2, (+)-CPI-CDPI2, and (−)-CPI-CDPI2 [(±)-(3bR*, 4aS*)-, (+)-(3bR,4aS)-, and (−)-(3bS,4aR)-deoxy-CC-1065] , 1988 .

[81]  M. Warpehoski,et al.  Molecular basis for sequence-specific DNA alkylation by CC-1065. , 1988, Biochemistry.

[82]  R. S. Coleman,et al.  Total synthesis of (+)-CC-1065 and ent-(-)-CC-1065 , 1988 .

[83]  D. Boger,et al.  Inverse electron demand Diels-Alder reactions of heterocyclic azadienes. Studies on the total synthesis of lavendamycin: investigative studies on the preparation of the CDE .beta.-carboline ring system and AB quinoline-5,8-quinone ring system , 1985 .

[84]  D. Boger,et al.  Total synthesis of lavendamycin methyl ester , 1985 .

[85]  D. Boger,et al.  PALLADIUM(0)-MEDIATED β-CARBOLINE SYNTHESIS: PREPARATION OF THE CDE RING SYSTEM OF LAVENDAMYCIN , 1984 .

[86]  D. Boger,et al.  Total synthesis of azafluoranthene alkaloids: rufescine and imeluteine , 1984 .

[87]  J. Panek,et al.  Palladium (O) mediated β-carboline synthesis: Preparation of the CDE ring system of lavendamycin , 1984 .

[88]  W. C. Krueger,et al.  CC-1065 (NSC 298223), a potent new antitumor agent improved production and isolation, characterization and antitumor activity. , 1981, The Journal of antibiotics.